drugset / Trial / NCT02651441
D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)
Phase 1/2
Unknown
60 enrolled
Shenzhen Hornetcorn Bio-technology Company, LTD
Affiliated Cancer Hospital & Institute of Guangzhou Medical University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of chemotherapy combined with dendritic activated cytokine-induced killer cell (D-CIK) for non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2016-02
- Primary completion
- 2019-05
- Completion
- 2019-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | D-CIK | Cell therapy | 8e+09 cells | Intravenous |
| Background | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |